Integra LifeSciences (IART) investor relations material

Demand and commercial strategy

• Procedure volumes in neurosurgery and tissue reconstruction were largely stable, supported by clinically necessary procedures and durable demand.

• Customers prioritize clinical evidence, differentiated products, supplier reliability, economic value, scale, established relationships, and easier contracting.

• A Chief Commercial Officer role created earlier in 2026 consolidated commercial and contracting activities to coordinate enterprise selling and use portfolio scale in customer discussions.

• Annual price gains have averaged ~1 point; cost efficiencies are needed to help offset wage, salary, and component-material inflation.

Specialty surgery

• Q3 specialty surgery grew ~4%; neurosurgery grew 6.5%, including a ~$7M Cincinnati flood headwind and favorable prior-year comparison; normalized growth was ~3.5%-4%.

• Q3 international specialty grew high single digits as supply availability improved; CereLink, CERTAS Valve, Bactiseal, DuraSeal, and cranial perforators contributed.

• Specialty surgery ranks No. 1 or No. 2 in most subsegments, No. 3 in ENT; niche products embedded in surgeon workflows and established relationships support differentiation.

• Neurosurgery demand is stable and largely trauma- or acute-based; no material impact from ACA subsidy concerns was seen, and sales-rep retention remained consistent over the past three years.

Tissue reconstruction

• PriMatrix, relaunched in Q4 2025, showed strong Q3 growth; through Q3, revenue was tracking to recover >50% of pre-recall levels.

• Integra Skin grew sequentially from Q2 to Q3 but below expectations; delayed availability of larger sizes and new competitors made share recovery slower than anticipated.

• Portfolio education using PriMatrix and Integra Skin is underway; expansion across accounts is planned through Q4 and into 2027.

• About 90% of wound reconstruction sales are inpatient; portfolio breadth, clinical evidence, and pricing aligned with the $127/cm² fixed reimbursement rate supported margins and reduced wastage exposure.

• SurgiMend 510(k) relaunch is planned, with a SurgiMend PMA expected in 2027 for implant-based breast reconstruction; a DuraSorb PMA is planned to follow.